What were RPG Life Sciences Ltd's latest quarterly results?
RPG Life Sciences Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -37.1%
- Revenue Growth YoY: +4.0%
- Operating Margin: 22.0%
RPG Life Sciences Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 27.6. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
RPG Life Sciences Ltd's latest quarterly results (Dec 2025) show
RPG Life Sciences Ltd's current PE ratio is 27.6x.
RPG Life Sciences Ltd has a debt-to-equity ratio of N/A.
RPG Life Sciences Ltd's current dividend yield is 1.07%.
RPG Life Sciences Ltd's shareholding pattern (Dec 2025)
RPG Life Sciences Ltd's promoter holding has remained stable recently.
RPG Life Sciences Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why RPG Life Sciences Ltd may be worth studying
RPG Life Sciences Ltd investment thesis summary:
RPG Life Sciences Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.